Free Trial
NASDAQ:CRIS

Curis Q1 2025 Earnings Report

Curis logo
$2.41 -0.07 (-2.82%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.44 +0.02 (+1.04%)
As of 05/2/2025 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Curis EPS Results

Actual EPS
N/A
Consensus EPS
-$1.39
Beat/Miss
N/A
One Year Ago EPS
N/A

Curis Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.37 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Curis Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Curis Earnings Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Curis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Curis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Curis and other key companies, straight to your email.

About Curis

Curis (NASDAQ:CRIS), a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

View Curis Profile

More Earnings Resources from MarketBeat